Idera Pharmaceuticals, Inc.

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Role: collaborator

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Role: lead

A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma

Role: lead

A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis

Role: lead

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

Role: lead

A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma

Role: collaborator

A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors

Role: lead

Trial of IMO-8400 in Adult Patients With Dermatomyositis

Role: lead

Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

Role: lead

Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients

Role: lead

Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients

Role: lead

Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma

Role: lead

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

Role: lead

Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401

Role: lead

Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation

Role: lead